Bocanegra-Pérez MS, Vicente-Barrero M,
Sosa-Henríquez M, Rodríguez-Bocanegra E, Limiñana-Cañal
JM, López-Márquez A, Pérez-Plasencia D, Ramos-Macías A. Bone metabolism and clinical study of
44 patients with bisphosphonate-related osteonecrosis of the jaws. Med Oral Patol
Oral Cir Bucal. 2012 Nov 1;17
(6):e948-55.
doi:10.4317/medoral.17946
http://dx.doi.org/doi:10.4317/medoral.17946
|
1. Rodan GA, Fleisch
HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692-6. |
|
|
|
|
|
2. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Management of cancer treatment-induced
bone loss in early breast and prostate cancer - a consensus paper of the
Belgian Bone Club. Osteoporos Int. 2007;18:1439-50. |
|
|
|
|
|
3. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic
acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-61. |
|
|
|
|
|
4. Delmas PD. The use of bisphosphonates
in the treatment of osteoporosis. Curr Opin Rheumatol. 2005;17:462-6. |
|
|
|
|
|
5. Watts NB. Bisphosphonate treatment of
osteoporosis. Clin Geriatr
Med. 2003;19:395-414. |
|
|
|
|
|
6. Jiménez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause
of drug-induced jaw osreonecrosis: an update. Med Oral Patol Oral Cir Bucal
2005;10:e88-91. |
|
|
|
|
|
7. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S et al. Osteonecrosis
of the jaw: more research needed. J Bone Miner Res. 2006;21:1503-5. |
|
|
|
|
|
8. Marx RE. Pamidronate (Aredia)
and zoledronate (Zometa)
induced avascular necrosis of the jaws: a growing
epidemic. J Oral Maxillofac
Surg. 2003;61:1115-18. |
|
|
|
|
|
9. Ruggiero
SL, Mehrotra B, Rosenberg
TJ, Engroff SL. Osteonecrosis of the jaws
associated with the use of bisphosphonates: a
review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34. |
|
|
|
|
|
10. Estefanía R, Ponte
R, Aguirre JM. Bisphosphonates and oral
pathology II. Osteonecrosis of the jaws: review of
the literature before 2005. Med Oral Patol Oral Cir
Bucal. 2006;11:e456-61. |
|
|
|
|
|
11. Advisory Task Force on Bisphosphonate-Related
Osteonecrosis of the Jaws, American Association of
Oral and Maxillofacial Surgeons. American Association of Oral and
Maxillofacial Surgeons position paper on bisphosphonate-related
osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76. |
|
|
|
|
|
12. Bagan
JV, Jimenez Y, Diaz JM,
Murillo J, Sanchis JM, Poveda
R, et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: Proposal for a modification of the
clinical classification. Oral Oncol. 2009;45:645-6. Epub 2008 Aug 19. |
|
|
|
|
|
13. Hellstein JW, Marek
CL. Bisphosphonates osteochemonecrosis
(bis-phossy jaw): is this phossy
jaw of the 21 st century? J Oral Maxillofac Surg. 2005;63:682-9. |
|
|
|
|
|
14. Bagan
J, Blade J, Cozar JM,
Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations
for the prevention, diagnosis, and treatment of osteonecrosis
of the jaw (ONJ) in cancer patients treated with bisphosphonates.
Med Oral Patol Oral Cir
Bucal. 2007;12:E336-40. |
|
|
|
|
|
15. Migliorati CA, Schubert MM, Peterson DE,
Seneda LM. Bisphosphonate-associated
osteonecrosis of mandibular
and maxillary bone: an emerging oral complication of supportive cancer
therapy. Cancer. 2005;104:83-93. |
|
|
|
|
|
16. Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology
Am Soc Hematol Educ Program. 2006:356-60,515. |
|
|
|
|
|
17. Maerevoet M, Martin C, Duck L.Osteonecrosis of the jaw and bisphosphonates.
N Engl J Med. 2005;353:99-102;
discussion 99-102. Erratum in: N Engl J Med. 2005;353:2728. |
|
|
|
|
|
18. Yarom N, Elad
S, Madrid C, Migliorati CA. Osteonecrosis
of the jaws induced by drugs other than bisphosphonates
- a call to update terminology in light of new data. Oral Oncol.
2010;46:e1. |
|
|
|
|
|
19. Bagan
JV, Jiménez Y, Murillo J, Hernández S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis
associated with bisphosphonates: multiple exposed
areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42:327-9. |
|
|
|
|
|
20. Badros A, Weikel
D, Salama A, Goloubeva O,
Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients:
clinical features and risk factors. J Clin Oncol. 2006;24:945-52. |
|
|
|
|
|
21. Bamias
A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I,
Bozas G, et al. Osteonecrosis of the jaw in cancer after
treatment with bisphosphonates: incidence and risk
factors. J Clin
Oncol. 2005;23:8580-7. |
|
|
|
|
|
22. Dore F, Filippi L, Biasotto
M, Chiandussi S, Cavalli
F, Di Lenarda R. Bone scintigraphy
and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med. 2009;50:30-5. |
|
|
|
|
|
23. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates.N
Engl J Med. 2005;353:99-102. |
|
|
|
|
|
24. Kos M, Kuebler JF, Luczak
K, Engelke W. Bisphosphonate-related
osteonecrosis of the jaws: a review of 34 cases and
evaluation of risk. J Craniomaxillofac Surg. 2010;38:255-9. |
|
|
|
|
|
25. Favia G, Pilolli
GP, Maiorano E. Histologic
and histomorphometric features of bisphosphonate-related osteonecrosis
of the jaws: an analysis of 31 cases with confocal
laser scanning microscopy. Bone. 2009;45:406-13. |
|
|
|
|
|
26. Bocanegra-Pérez S,
Vicente-Barrero M, Sosa-Henríquez M, Gebaguer
Blanco A, Knezevic M, Castellano-Navarro JM. Osteonecrosis maxilar secundaria al uso de bisfosfonatos por vía oral. Exposición de tres casos
clínicos relacionados con alendronato. Rev Med Chil.
2009;137:271-5. |
|
|
|
|
|
27. Aragon-Ching JB, Ning
YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et
al. Higher incidence of Osteonecrosis of the Jaw
(ONJ) in patients with metastatic castration resistant prostate cancer
treated with anti-angiogenic agents. Cancer Invest. 2009;27:221-6. |
|
|
|
|
|
28. Stopeck A. Denosumab
findings in metastatic breast cancer. Clin Adv Hematol Oncol. 2010;8:159-60. |
|
|
|
|
|
29. Pérez SB, Barrero
MV, Hernández MS, Knezevic
M, Navarro JM, Millares J. Bisphosphonate-associated
osteonecrosis of the jaw. A proposal for
conservative treatment. Med Oral Patol Oral Cir Bucal. 2008;13:E770-3. |
|
|
|
|
|
30. Adornato MC, Morcos
I, Rozanski J. The treatment of bisphosphonate
associated osteonecrosis of the jaws with bone
resection and autologous platelet-derived growth
factors. J Am Dent
Assoc. 2007;138:971-7. |
|